PKD: Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)

Sponsor

Agios Pharmaceuticals, Inc. (Industry)

Overall Status

Recruiting

CT.gov ID

NCT04964323

Collaborator

(none)

Enrollment

Locations

Anticipated Duration (Months)

Patients Per Site

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary objective of this study is to understand and characterize the health-related quality of life (HRQoL) and disease burden of adult participants with PK deficiency receiving routine clinical care. This study is an observational (i.e., noninterventional), longitudinal, multicenter, global registry for participants with PK deficiency, a rare nonspherocytic hemolytic anemia.

This study will be open for enrollment for 2 years and all enrolled participants will be followed prospectively for up to 96 weeks.

Data will be collected from participants who have provided informed consent and authorization pursuant to applicable laws and regulations.

Condition or Disease	Intervention/Treatment	Phase
Pyruvate Kinase Deficiency Pyruvate Kinase Deficiency Anemia Anemia Anemia, Hemolytic

Detailed Description

Participants aged ≥18 years and previously enrolled in Study AG348-C-008 (NCT03481738) will be eligible to participate in this study. Data will be submitted via electronic patient-reported outcomes (ePRO) application.

All data collection efforts will abide by this protocol and be prospectively disclosed in the study informed consent. This study, with the appropriate participant (and or parent/guardian) consent/assent, may incorporate retrospective data from other properly consented studies done for the purpose of examining the longitudinal natural history of PK deficiency.

Study Design

Study Type:

Observational [Patient Registry]

Anticipated Enrollment :

75 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Pyruvate Kinase Deficiency Global Longitudinal Registry: Patient-Reported Outcomes

Actual Study Start Date :

Jul 2, 2021

Anticipated Primary Completion Date :

Aug 1, 2025

Anticipated Study Completion Date :

Aug 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
PK Deficiency Diagnosed Participants previously diagnosed with PK deficiency in Study AG348-C-008 (NCT03481738), will receive routine clinical care.

Outcome Measures

Primary Outcome Measures

Change from Baseline in Pyruvate Kinase Deficiency Diary (PKDD) Score [Baseline, up to Day 672]
The PKDD is a 7-item measure of the core signs and symptoms of PK deficiency. The score range is 25 to 76, with higher scores indicating a higher disease burden.
Change from Baseline in Pyruvate Kinase Deficiency Impact Assessment (PKDIA) Score [Baseline, up to Day 672]
The PKDIA is a 12-item measure of the impacts of PK deficiency on patients' HRQoL. The score range is 30 to 76, with higher scores indicating a higher disease burden.
Change from Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI: SHP) 2.0 Score [Baseline, up to Day 672]
WPAI:SHP is a 6-question participant-rated questionnaire to determine the amount of absenteeism, presenteeism, work productivity loss, and daily activity impairment attributable to PK deficiency for a period of 7 days prior to each visit. It yields 4 sub-scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). These sub-scores are transformed to impairment percentages (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.
Change from Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) [Baseline, up to Day 672]
FACT-An is composed of five subscales: Physical Well-Being [score range 0-28], Social/Family Well-Being [score range 0-28], Emotional Well-Being [score range 0-24], and Functional Well-Being [score range 0-28] and specific questions concerning anemia [score range 0-80]. The score at each item is summed. The sum is multiplied by the number of items in the subscale and then divided by the number of items answered. This produces the subscale score. The subscale scores are added to derive a total score [score range 0-188]. A higher score indicates better quality of life.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Participant must be greater than or equal to (≥)18 years of age;
Participant must be enrolled in Study AG348-C-008.

Exclusion Criteria:

Participant is enrolled in an Agios-sponsored clinical study involving treatment with a pyruvate kinase activator.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Massachusetts General Hospital	Boston	Massachusetts	United States	02114
2	Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico	Milan		Italy	20122
3	Universitair Medisch Centrum Utrecht	Utrecht		Netherlands	3508 GA
4	Hospital Infantil Universitario Niño Jesus - PIN	Madrid		Spain	28009
5	Hammersmith Hospital	London		United Kingdom	W12 0HS